Forbius

Forbius:
Protein engineering platforms /design highly active & selective inhibitors of TGF-Beta and EGFR pathways for onco and fibrotic diseases. YM Bioscience spin-out (acquired by GILD). Ilia Tikhomirov, CEO, involved in devt of anti-EGFR agent and JAK inhibitor at YM. AVID100, anti-EGFR ADC in Ph 2a in EGFR IHC3+ cancer in triple (-) breast cancer, head & neck squamous cell carcinoma, and NSCLC. Ph 2a endpts incl ORR, PFS, PK, and safety. Ph 1 complete in all comers, good safety. AVID200, isoform selective TGF-Beta inhibitor in systemic sclerosis, myelofibrosis, scleroderma, and IO (+ in combo w checkpoint blockade). 3 Ph 1s to be started in parallel, open-label.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - West South Central
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Immuno-Oncology, Oncology
Listing
Private
Website:
Profiles:
Address:
101 W 6TH Street
Suite 501
Austin, TX 78701
United States
Suite 501
Austin, TX 78701
United States
Presentation:
More info:
My account:
Company Participants at Summer 2020 NYC Private Company Showcase
- Ilia Tikhomirov, President and CEO
Lead Programs
AVID100 anti-EGFR ADC
Indication | Phase |
---|---|
SCCHN | 2 |
NSCLC | 2 |
TNBC | 2 |
AVID200 TGF-ß inhibitor
Indication | Phase |
---|---|
Immune Oncology | 1 |
Systemic Sclerosis | 1 |
Myelofibrosis | 1 |